|  |
| --- |
| **STUDY PROTOCOL INFORMATION** |
| **Reference Number:[[1]](#footnote-0)** |  |
| **UPOU IREB Code:[[2]](#footnote-1)** |  |
| **Study Protocol Title:** |  |
| **Principal Investigator:** |  |
| **Study Protocol Submission Date:** |  |

**INSTRUCTIONS**

|  |  |
| --- | --- |
| To the Principal Investigator: | Does your research involve human participants? * Yes
* No

Please indicate in the space provided below whether or not the specified element is addressed by the informed consent form (ICF). To facilitate the evaluation of the assessment point, indicate the page and paragraph where this information can be found.  |
| To the Primary Reviewer: | Please evaluate how the elements outlined below have been appropriately addressed by the informed consent form (ICF), as applicable, and by confirming the submitted information and putting your comments in the space provided under “REVIEWER COMMENTS.” In your comments, ensure that **vulnerability, recruitment process, and process of applying research ethics** are always assessed in the context of the study protocol and the participant. Finalize your review by indicating your conclusions under “RECOMMENDED ACTION” and signing in space provided for the primary reviewer.  |
|  | **To be filled out by the PI** |  |
| **Essential Elements****(as applicable to the study)** | Indicate if the ICF has the specified element | Page and paragraph where element is found | **REVIEWER COMMENTS** |
|  |  |  |  |
| 1. Statement that the study involves research
 |  |  |  |  |
| 1. Statement describing the purpose of the study
 |  |  |  |  |
| 1. Study-related treatments and probability for random assignment
 |  |  |  |  |
| 1. Responsibilities of the participant
 |  |  |  |  |
| 1. Expected duration of participation in the study
 |  |  |  |  |
| 1. Approximate number of participants in the study
 |  |  |  |  |
| 1. Study aspects that are experimental
 |  |  |  |  |
| 1. Reasonably expected benefits; or absence of direct benefit to participants, as applicable
 |  |  |  |  |
| 1. Expected benefits to the community or to society, or contributions to scientific knowledge
 |  |  |  |  |
| 1. Compensation or insurance or treatment entitlements of the participant in case of study-related injury
 |  |  |  |  |
| 1. Anticipated payment, if any, to the participant in the course of the study; whether money or other forms of material goods, and if so, the kind and amount
 |  |  |  |  |
| 1. Compensation (or no plans of compensation) for the participant or the participant’s family or dependents in case of disability or death resulting from study-related injuries
 |  |  |  |  |
| 1. Anticipated expenses, if any, to the participant in the course of the study
 |  |  |  |  |
| 1. Statement that participation is voluntary, and that participant may withdraw anytime without penalty or loss of benefit to which the participant is entitled
 |  |  |  |  |
| 1. Statement that the records identifying the participant will be kept confidential and will not be made publicly available, to the extent permitted by law; and that the identity of the participant will remain confidential in the event the study results are published; including limitations to the investigator’s ability to guarantee confidentiality
 |  |  |  |  |
| 1. Statement that the participant or participant’s legally acceptable representative will be informed in a timely manner if information becomes available that may be relevant to willingness of the participant to continue to participation
 |  |  |  |  |
| 1. Statement describing access of participant to the result of the study
 |  |  |  |  |
| 1. Statement describing extent of participant’s right to access his/her records (or lack thereof *vis à vis* pending request for approval of non or partial disclosure)
 |  |  |  |  |
| 1. Foreseeable circumstances and reasons under which participation in the study may be terminated
 |  |  |  |  |
| 1. Sponsor, institutional affiliation of the investigators, and nature and sources of funds
 |  |  |  |  |
| 1. Person(s) to contact in the study team for further information regarding the study and whom to contact in the event of study-related injury
 |  |  |  |  |
| 1. Statement that the UPOU IREC has approved the study, and may be reached through the following contact for information regarding rights of study participants, including grievances and complaints:

**Name of UPOU IREC Chair****Address:** UPOU HQ**Email:** **Tel:** **Mobile:**  |  |  |  |  |
| 1. Comprehensibility of language used
 |  |  |
| 1. Other comments not addressed by items 1-24
 |  |  |
| **RECOMMENDED ACTION:** |
| * APPROVE
 |
| * MINOR MODIFICATIONS
 |
| * MAJOR MODIFICATIONS
* DISAPPROVE
* PENDING, IF MAJOR CLARIFICATIONS ARE REQUIRED BEFORE A DECISION CAN BE MADE
 |
| **JUSTIFICATION FOR RECOMMENDED ACTION** |
| **PRIMARY REVIEWER** |  | Signature  |  |
| Date: <dd/mm/yyyy> |  | Name | <Title, Name, Surname> |

1. To be issued upon RPC registration/submission [↑](#footnote-ref-0)
2. To be issued upon initial processing by UPOU IREC [↑](#footnote-ref-1)